Multiple Sclerosis Drugs Market Report 2026

The multiple sclerosis drugs market size has grown rapidly in recent years. It will grow from $33.46 billion in 2025 to $37.67 billion in 2026 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to limited availability of ms therapies, growing prevalence of multiple sclerosis, increasing awareness among patients and physicians, reliance on interferon-based therapies, expansion of hospital and retail pharmacy networks.

The multiple sclerosis drugs market size is expected to see rapid growth in the next few years. It will grow to $61.43 billion in 2030 at a compound annual growth rate (CAGR) of 13%. The growth in the forecast period can be attributed to development of novel monoclonal antibodies, expansion of oral disease-modifying therapies, integration of personalized medicine in ms treatment, rising investment in r&d for emerging therapies, growing adoption of digital health monitoring and telemedicine platforms. Major trends in the forecast period include rising adoption of disease-modifying therapies for multiple sclerosis, growth in personalized and targeted ms treatment approaches, expansion of hospital and retail pharmacy distribution channels, increasing preference for oral and parenteral routes of administration, emergence of novel immunomodulators, immunosuppressants, and monoclonal antibodies.

The growth of the multiple sclerosis drugs market is supported by initiatives from both government bodies and non-government organizations. Governments and non-government organizations finance a range of schemes and programs aimed at improving the quality of life of individuals living with multiple sclerosis (MS). For example, the Government of Alberta, in collaboration with the Department of Economic Development, Trade, and Tourism in Canada, invested $1 million in the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo) to advance research and innovation focused on improving the understanding and treatment of MS. CanProCo brings together the efforts of nearly 50 multiple sclerosis researchers from various disciplines across Canada. Additional funding was provided by Canada Brain Research, Biogen Canada, the MS Society of Canada, and Hoffmann-La Roche Limited (Roche Canada), raising the total funding to $10 million. Such financial support from government and non-government organizations plays a key role in driving the growth of the multiple sclerosis drugs market.

Major companies operating in the multiple sclerosis drugs market are concentrating on the development of innovative solutions to enhance treatment effectiveness, improve patient quality of life, and address the varied needs of people with multiple sclerosis. Innovative solutions include novel approaches, therapies, and technologies designed to better manage disease progression and symptoms. For instance, in September 2024, Genentech, a US-based biotechnology company, announced that the U.S. Food and Drug Administration approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis and primary progressive multiple sclerosis. Ocrevus Zunovo is the first and only subcutaneous injection for MS administered by healthcare professionals twice a year, with an administration time of approximately 10 minutes, offering patients additional and more convenient treatment options.

In March 2024, Juvisé Pharmaceuticals, a France-based pharmaceutical company, acquired Actelion Pharmaceuticals Ltd. for an undisclosed amount. Through this acquisition, Juvisé Pharmaceuticals aims to expand its product portfolio and improve patient care by securing global commercial rights to Ponvory for the treatment of relapsing multiple sclerosis outside the United States and Canada. Actelion Pharmaceuticals Ltd. is a Switzerland-based pharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.

Major companies operating in the multiple sclerosis drugs market are Biogen Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Bayer HealthCare LLC, Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Acorda Therapeutics Inc., EMD Serono Inc., AbbVie Inc., Bayer Schering Pharma AG, Bristol-Myers Squibb Company, Johnson & Johnson, Mitsubishi Tanabe Pharma Corporation, Opexa Therapeutics Inc., Receptos Inc., Synthon Pharmaceuticals Inc., TG Therapeutics Inc., Alkermes plc, Amgen Inc., Atara Biotherapeutics Inc., Celgene Corporation, Genzyme Corporation.

North America was the largest region in the global multiple sclerosis drug market in 2025. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple sclerosis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the multiple sclerosis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the multiple sclerosis drugs market by increasing the cost of imported active pharmaceutical ingredients, monoclonal antibodies, and biologics, impacting supply chains and drug affordability. Hospital and retail pharmacies in North America and Europe, which rely heavily on imports, are most affected. However, tariffs have also encouraged local production, investment in domestic manufacturing, and innovation in cost-effective MS therapies, improving long-term accessibility and market resilience.

The multiple sclerosis drugs market research report is one of a series of new reports that provides multiple sclerosis drugs market statistics, including multiple sclerosis drugs industry global market size, regional shares, competitors with a multiple sclerosis drugs market share, detailed multiple sclerosis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the multiple sclerosis drugs industry. This multiple sclerosis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Multiple sclerosis drugs are medications developed to slow the progression of disability and reduce the frequency of disease relapses. These medicines are known as disease-modifying treatments and work by targeting specific proteins on the surface of immune cells, thereby lowering the number of white blood cells to help prevent multiple sclerosis relapses. This effect can reduce the tendency of white blood cells to cause nerve damage.

The primary drug classes of multiple sclerosis treatments include immunomodulators, immunosuppressants, interferons, and others. Immunomodulators are a group of drugs that mainly act on immune pathways and are also used in the treatment of multiple myeloma and certain other cancers. These medications are administered through oral and parenteral routes and are distributed via hospital pharmacies, retail pharmacies, and online stores.

The multiple sclerosis drug market consists of sales of lemtrada, novantrone, ocrevus, and tysabri. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.